49,981 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 49,981 shares of the biopharmaceutical company’s stock, valued at approximately $2,033,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Canada Pension Plan Investment Board purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter worth about $52,000. Capula Management Ltd bought a new position in Halozyme Therapeutics during the 2nd quarter valued at approximately $208,000. Eqis Capital Management Inc. raised its position in shares of Halozyme Therapeutics by 16.8% in the 2nd quarter. Eqis Capital Management Inc. now owns 5,631 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 808 shares in the last quarter. CIBC Asset Management Inc raised its position in shares of Halozyme Therapeutics by 15.1% in the 3rd quarter. CIBC Asset Management Inc now owns 5,789 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 758 shares in the last quarter. Finally, Inspire Investing LLC bought a new position in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $236,000. Hedge funds and other institutional investors own 90.56% of the company’s stock.

In other news, Director Connie Matsui sold 32,000 shares of the stock in a transaction that occurred on Friday, November 5th. The shares were sold at an average price of $40.38, for a total value of $1,292,160.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Helen Torley sold 50,000 shares of the stock in a transaction that occurred on Monday, November 8th. The stock was sold at an average price of $39.82, for a total transaction of $1,991,000.00. The disclosure for this sale can be found here. 2.60% of the stock is currently owned by corporate insiders.

Several analysts recently weighed in on HALO shares. Zacks Investment Research downgraded Halozyme Therapeutics from a “hold” rating to a “strong sell” rating and set a $30.00 price target on the stock. in a research note on Thursday. SVB Leerink cut their target price on Halozyme Therapeutics from $50.00 to $48.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 3rd. raised their price target on Halozyme Therapeutics from $27.00 to $48.00 and gave the stock a “buy” rating in a research note on Thursday, December 2nd. Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $60.00 to $58.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 24th. Finally, TheStreet raised Halozyme Therapeutics from a “c+” rating to a “b” rating in a report on Monday, September 20th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Buy” and an average price target of $51.25.

Halozyme Therapeutics stock opened at $35.56 on Friday. The company has a market capitalization of $5.01 billion, a PE ratio of 12.75 and a beta of 1.30. Halozyme Therapeutics, Inc. has a fifty-two week low of $31.79 and a fifty-two week high of $56.40. The company has a debt-to-equity ratio of 2.79, a quick ratio of 8.50 and a current ratio of 8.99. The company has a 50 day moving average price of $36.70 and a 200-day moving average price of $39.60.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, November 2nd. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $1.06. The business had revenue of $115.83 million for the quarter, compared to the consensus estimate of $101.94 million. Halozyme Therapeutics had a return on equity of 187.85% and a net margin of 88.36%. During the same period in the prior year, the firm posted $0.25 earnings per share. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 1.82 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Story: What is a Candlestick Chart?

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.